Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection

Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%–80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstruc...
Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Dore, Gregory J. [verfasserIn] Lawitz, Eric Hézode, Christophe Shafran, Stephen D. Ramji, Alnoor Tatum, Harvey A. Taliani, Gloria Tran, Albert Brunetto, Maurizia R. Zaltron, Serena Strasser, Simone I. Weis, Nina Ghesquiere, Wayne Lee, Samuel S. Larrey, Dominique Pol, Stanislas Harley, Hugh George, Jacob Fung, Scott K. de Lédinghen, Victor Hagens, Peggy McPhee, Fiona Hernandez, Dennis Cohen, David Cooney, Elizabeth Noviello, Stephanie Hughes, Eric A.

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2015

Schlagwörter:	NS5A Replication Complex Inhibitor Combination Therapy DAA Antiviral

Umfang:	3307

Übergeordnetes Werk:	Enthalten in: Ubiquitin protease Ubp8 is necessary for - Leo, Manuela ELSEVIER, 2018, official publication of the American Gastroenterological Association, Stanford, Calif
Übergeordnetes Werk:	volume:148 ; year:2015 ; number:2 ; pages:355-3661 ; extent:3307

Links:	Volltext

DOI / URN:	10.1053/j.gastro.2014.10.007

Katalog-ID:	ELV013412817

Internformat


LEADER	01000caa a22002652 4500
001	ELV013412817
003	DE-627
005	20230623105037.0
007	cr uuu---uuuuu
008	180602s2015 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1053/j.gastro.2014.10.007 \|2 doi
028	5	2	\|a GBVA2015021000015.pica
035			\|a (DE-627)ELV013412817
035			\|a (ELSEVIER)S0016-5085(14)01206-2
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0		\|a 610
082	0	4	\|a 610 \|q DE-600
082	0	4	\|a 570 \|q VZ
084			\|a BIODIV \|q DE-30 \|2 fid
084			\|a 35.70 \|2 bkl
084			\|a 42.12 \|2 bkl
084			\|a 42.15 \|2 bkl
100	1		\|a Dore, Gregory J. \|e verfasserin \|4 aut
245	1	0	\|a Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection
264		1	\|c 2015
300			\|a 3307
336			\|a nicht spezifiziert \|b zzz \|2 rdacontent
337			\|a nicht spezifiziert \|b z \|2 rdamedia
338			\|a nicht spezifiziert \|b zu \|2 rdacarrier
520			\|a Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%–80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy.
650		7	\|a NS5A Replication Complex Inhibitor \|2 Elsevier
650		7	\|a Combination Therapy \|2 Elsevier
650		7	\|a DAA \|2 Elsevier
650		7	\|a Antiviral \|2 Elsevier
700	1		\|a Lawitz, Eric \|4 oth
700	1		\|a Hézode, Christophe \|4 oth
700	1		\|a Shafran, Stephen D. \|4 oth
700	1		\|a Ramji, Alnoor \|4 oth
700	1		\|a Tatum, Harvey A. \|4 oth
700	1		\|a Taliani, Gloria \|4 oth
700	1		\|a Tran, Albert \|4 oth
700	1		\|a Brunetto, Maurizia R. \|4 oth
700	1		\|a Zaltron, Serena \|4 oth
700	1		\|a Strasser, Simone I. \|4 oth
700	1		\|a Weis, Nina \|4 oth
700	1		\|a Ghesquiere, Wayne \|4 oth
700	1		\|a Lee, Samuel S. \|4 oth
700	1		\|a Larrey, Dominique \|4 oth
700	1		\|a Pol, Stanislas \|4 oth
700	1		\|a Harley, Hugh \|4 oth
700	1		\|a George, Jacob \|4 oth
700	1		\|a Fung, Scott K. \|4 oth
700	1		\|a de Lédinghen, Victor \|4 oth
700	1		\|a Hagens, Peggy \|4 oth
700	1		\|a McPhee, Fiona \|4 oth
700	1		\|a Hernandez, Dennis \|4 oth
700	1		\|a Cohen, David \|4 oth
700	1		\|a Cooney, Elizabeth \|4 oth
700	1		\|a Noviello, Stephanie \|4 oth
700	1		\|a Hughes, Eric A. \|4 oth
773	0	8	\|i Enthalten in \|n HighWire Press \|a Leo, Manuela ELSEVIER \|t Ubiquitin protease Ubp8 is necessary for \|d 2018 \|d official publication of the American Gastroenterological Association \|g Stanford, Calif \|w (DE-627)ELV000307017
773	1	8	\|g volume:148 \|g year:2015 \|g number:2 \|g pages:355-3661 \|g extent:3307
856	4	0	\|u https://doi.org/10.1053/j.gastro.2014.10.007 \|3 Volltext
912			\|a GBV_USEFLAG_U
912			\|a GBV_ELV
912			\|a SYSFLAG_U
912			\|a FID-BIODIV
912			\|a SSG-OLC-PHA
936	b	k	\|a 35.70 \|j Biochemie: Allgemeines \|q VZ
936	b	k	\|a 42.12 \|j Biophysik \|q VZ
936	b	k	\|a 42.15 \|j Zellbiologie \|q VZ
951			\|a AR
952			\|d 148 \|j 2015 \|e 2 \|h 355-3661 \|g 3307
953			\|2 045F \|a 610

Indexfelder

author_variant	g j d gj gjd
matchkey_str	doregregoryjlawitzerichzodechristophesha:2015----:altsipupgnefrnnrbvrnsoifrotpgnefrnnrbvrnlnadeueteuainf
hierarchy_sort_str	2015
bklnumber	35.70 42.12 42.15
publishDate	2015
allfields	10.1053/j.gastro.2014.10.007 doi GBVA2015021000015.pica (DE-627)ELV013412817 (ELSEVIER)S0016-5085(14)01206-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl 42.15 bkl Dore, Gregory J. verfasserin aut Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection 2015 3307 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%–80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy. NS5A Replication Complex Inhibitor Elsevier Combination Therapy Elsevier DAA Elsevier Antiviral Elsevier Lawitz, Eric oth Hézode, Christophe oth Shafran, Stephen D. oth Ramji, Alnoor oth Tatum, Harvey A. oth Taliani, Gloria oth Tran, Albert oth Brunetto, Maurizia R. oth Zaltron, Serena oth Strasser, Simone I. oth Weis, Nina oth Ghesquiere, Wayne oth Lee, Samuel S. oth Larrey, Dominique oth Pol, Stanislas oth Harley, Hugh oth George, Jacob oth Fung, Scott K. oth de Lédinghen, Victor oth Hagens, Peggy oth McPhee, Fiona oth Hernandez, Dennis oth Cohen, David oth Cooney, Elizabeth oth Noviello, Stephanie oth Hughes, Eric A. oth Enthalten in HighWire Press Leo, Manuela ELSEVIER Ubiquitin protease Ubp8 is necessary for 2018 official publication of the American Gastroenterological Association Stanford, Calif (DE-627)ELV000307017 volume:148 year:2015 number:2 pages:355-3661 extent:3307 https://doi.org/10.1053/j.gastro.2014.10.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ 42.15 Zellbiologie VZ AR 148 2015 2 355-3661 3307 045F 610
spelling	10.1053/j.gastro.2014.10.007 doi GBVA2015021000015.pica (DE-627)ELV013412817 (ELSEVIER)S0016-5085(14)01206-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl 42.15 bkl Dore, Gregory J. verfasserin aut Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection 2015 3307 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%–80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy. NS5A Replication Complex Inhibitor Elsevier Combination Therapy Elsevier DAA Elsevier Antiviral Elsevier Lawitz, Eric oth Hézode, Christophe oth Shafran, Stephen D. oth Ramji, Alnoor oth Tatum, Harvey A. oth Taliani, Gloria oth Tran, Albert oth Brunetto, Maurizia R. oth Zaltron, Serena oth Strasser, Simone I. oth Weis, Nina oth Ghesquiere, Wayne oth Lee, Samuel S. oth Larrey, Dominique oth Pol, Stanislas oth Harley, Hugh oth George, Jacob oth Fung, Scott K. oth de Lédinghen, Victor oth Hagens, Peggy oth McPhee, Fiona oth Hernandez, Dennis oth Cohen, David oth Cooney, Elizabeth oth Noviello, Stephanie oth Hughes, Eric A. oth Enthalten in HighWire Press Leo, Manuela ELSEVIER Ubiquitin protease Ubp8 is necessary for 2018 official publication of the American Gastroenterological Association Stanford, Calif (DE-627)ELV000307017 volume:148 year:2015 number:2 pages:355-3661 extent:3307 https://doi.org/10.1053/j.gastro.2014.10.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ 42.15 Zellbiologie VZ AR 148 2015 2 355-3661 3307 045F 610
allfields_unstemmed	10.1053/j.gastro.2014.10.007 doi GBVA2015021000015.pica (DE-627)ELV013412817 (ELSEVIER)S0016-5085(14)01206-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl 42.15 bkl Dore, Gregory J. verfasserin aut Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection 2015 3307 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%–80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy. NS5A Replication Complex Inhibitor Elsevier Combination Therapy Elsevier DAA Elsevier Antiviral Elsevier Lawitz, Eric oth Hézode, Christophe oth Shafran, Stephen D. oth Ramji, Alnoor oth Tatum, Harvey A. oth Taliani, Gloria oth Tran, Albert oth Brunetto, Maurizia R. oth Zaltron, Serena oth Strasser, Simone I. oth Weis, Nina oth Ghesquiere, Wayne oth Lee, Samuel S. oth Larrey, Dominique oth Pol, Stanislas oth Harley, Hugh oth George, Jacob oth Fung, Scott K. oth de Lédinghen, Victor oth Hagens, Peggy oth McPhee, Fiona oth Hernandez, Dennis oth Cohen, David oth Cooney, Elizabeth oth Noviello, Stephanie oth Hughes, Eric A. oth Enthalten in HighWire Press Leo, Manuela ELSEVIER Ubiquitin protease Ubp8 is necessary for 2018 official publication of the American Gastroenterological Association Stanford, Calif (DE-627)ELV000307017 volume:148 year:2015 number:2 pages:355-3661 extent:3307 https://doi.org/10.1053/j.gastro.2014.10.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ 42.15 Zellbiologie VZ AR 148 2015 2 355-3661 3307 045F 610
allfieldsGer	10.1053/j.gastro.2014.10.007 doi GBVA2015021000015.pica (DE-627)ELV013412817 (ELSEVIER)S0016-5085(14)01206-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl 42.15 bkl Dore, Gregory J. verfasserin aut Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection 2015 3307 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%–80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy. NS5A Replication Complex Inhibitor Elsevier Combination Therapy Elsevier DAA Elsevier Antiviral Elsevier Lawitz, Eric oth Hézode, Christophe oth Shafran, Stephen D. oth Ramji, Alnoor oth Tatum, Harvey A. oth Taliani, Gloria oth Tran, Albert oth Brunetto, Maurizia R. oth Zaltron, Serena oth Strasser, Simone I. oth Weis, Nina oth Ghesquiere, Wayne oth Lee, Samuel S. oth Larrey, Dominique oth Pol, Stanislas oth Harley, Hugh oth George, Jacob oth Fung, Scott K. oth de Lédinghen, Victor oth Hagens, Peggy oth McPhee, Fiona oth Hernandez, Dennis oth Cohen, David oth Cooney, Elizabeth oth Noviello, Stephanie oth Hughes, Eric A. oth Enthalten in HighWire Press Leo, Manuela ELSEVIER Ubiquitin protease Ubp8 is necessary for 2018 official publication of the American Gastroenterological Association Stanford, Calif (DE-627)ELV000307017 volume:148 year:2015 number:2 pages:355-3661 extent:3307 https://doi.org/10.1053/j.gastro.2014.10.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ 42.15 Zellbiologie VZ AR 148 2015 2 355-3661 3307 045F 610
allfieldsSound	10.1053/j.gastro.2014.10.007 doi GBVA2015021000015.pica (DE-627)ELV013412817 (ELSEVIER)S0016-5085(14)01206-2 DE-627 ger DE-627 rakwb eng 610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl 42.15 bkl Dore, Gregory J. verfasserin aut Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection 2015 3307 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%–80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy. NS5A Replication Complex Inhibitor Elsevier Combination Therapy Elsevier DAA Elsevier Antiviral Elsevier Lawitz, Eric oth Hézode, Christophe oth Shafran, Stephen D. oth Ramji, Alnoor oth Tatum, Harvey A. oth Taliani, Gloria oth Tran, Albert oth Brunetto, Maurizia R. oth Zaltron, Serena oth Strasser, Simone I. oth Weis, Nina oth Ghesquiere, Wayne oth Lee, Samuel S. oth Larrey, Dominique oth Pol, Stanislas oth Harley, Hugh oth George, Jacob oth Fung, Scott K. oth de Lédinghen, Victor oth Hagens, Peggy oth McPhee, Fiona oth Hernandez, Dennis oth Cohen, David oth Cooney, Elizabeth oth Noviello, Stephanie oth Hughes, Eric A. oth Enthalten in HighWire Press Leo, Manuela ELSEVIER Ubiquitin protease Ubp8 is necessary for 2018 official publication of the American Gastroenterological Association Stanford, Calif (DE-627)ELV000307017 volume:148 year:2015 number:2 pages:355-3661 extent:3307 https://doi.org/10.1053/j.gastro.2014.10.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA 35.70 Biochemie: Allgemeines VZ 42.12 Biophysik VZ 42.15 Zellbiologie VZ AR 148 2015 2 355-3661 3307 045F 610
language	English
source	Enthalten in Ubiquitin protease Ubp8 is necessary for Stanford, Calif volume:148 year:2015 number:2 pages:355-3661 extent:3307
sourceStr	Enthalten in Ubiquitin protease Ubp8 is necessary for Stanford, Calif volume:148 year:2015 number:2 pages:355-3661 extent:3307
format_phy_str_mv	Article
bklname	Biochemie: Allgemeines Biophysik Zellbiologie
institution	findex.gbv.de
topic_facet	NS5A Replication Complex Inhibitor Combination Therapy DAA Antiviral
dewey-raw	610
isfreeaccess_bool	false
container_title	Ubiquitin protease Ubp8 is necessary for
authorswithroles_txt_mv	Dore, Gregory J. @@aut@@ Lawitz, Eric @@oth@@ Hézode, Christophe @@oth@@ Shafran, Stephen D. @@oth@@ Ramji, Alnoor @@oth@@ Tatum, Harvey A. @@oth@@ Taliani, Gloria @@oth@@ Tran, Albert @@oth@@ Brunetto, Maurizia R. @@oth@@ Zaltron, Serena @@oth@@ Strasser, Simone I. @@oth@@ Weis, Nina @@oth@@ Ghesquiere, Wayne @@oth@@ Lee, Samuel S. @@oth@@ Larrey, Dominique @@oth@@ Pol, Stanislas @@oth@@ Harley, Hugh @@oth@@ George, Jacob @@oth@@ Fung, Scott K. @@oth@@ de Lédinghen, Victor @@oth@@ Hagens, Peggy @@oth@@ McPhee, Fiona @@oth@@ Hernandez, Dennis @@oth@@ Cohen, David @@oth@@ Cooney, Elizabeth @@oth@@ Noviello, Stephanie @@oth@@ Hughes, Eric A. @@oth@@
publishDateDaySort_date	2015-01-01T00:00:00Z
hierarchy_top_id	ELV000307017
dewey-sort	3610
id	ELV013412817
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV013412817</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623105037.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1053/j.gastro.2014.10.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015021000015.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV013412817</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0016-5085(14)01206-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.15</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dore, Gregory J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3307</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%–80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NS5A Replication Complex Inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Combination Therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DAA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antiviral</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lawitz, Eric</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hézode, Christophe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shafran, Stephen D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ramji, Alnoor</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tatum, Harvey A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taliani, Gloria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tran, Albert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brunetto, Maurizia R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zaltron, Serena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Strasser, Simone I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weis, Nina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ghesquiere, Wayne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Samuel S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Larrey, Dominique</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pol, Stanislas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Harley, Hugh</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">George, Jacob</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fung, Scott K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Lédinghen, Victor</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hagens, Peggy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McPhee, Fiona</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hernandez, Dennis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cohen, David</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cooney, Elizabeth</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Noviello, Stephanie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hughes, Eric A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">HighWire Press</subfield><subfield code="a">Leo, Manuela ELSEVIER</subfield><subfield code="t">Ubiquitin protease Ubp8 is necessary for</subfield><subfield code="d">2018</subfield><subfield code="d">official publication of the American Gastroenterological Association</subfield><subfield code="g">Stanford, Calif</subfield><subfield code="w">(DE-627)ELV000307017</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:148</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:355-3661</subfield><subfield code="g">extent:3307</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1053/j.gastro.2014.10.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.15</subfield><subfield code="j">Zellbiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">148</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">355-3661</subfield><subfield code="g">3307</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
author	Dore, Gregory J.
spellingShingle	Dore, Gregory J. ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 bkl 42.15 Elsevier NS5A Replication Complex Inhibitor Elsevier Combination Therapy Elsevier DAA Elsevier Antiviral Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection
authorStr	Dore, Gregory J.
ppnlink_with_tag_str_mv	@@773@@(DE-627)ELV000307017
format	electronic Article
dewey-ones	610 - Medicine & health 570 - Life sciences; biology
delete_txt_mv	keep
author_role	aut
collection	elsevier
remote_str	true
illustrated	Not Illustrated
topic_title	610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl 42.15 bkl Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection NS5A Replication Complex Inhibitor Elsevier Combination Therapy Elsevier DAA Elsevier Antiviral Elsevier
topic	ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 bkl 42.15 Elsevier NS5A Replication Complex Inhibitor Elsevier Combination Therapy Elsevier DAA Elsevier Antiviral
topic_unstemmed	ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 bkl 42.15 Elsevier NS5A Replication Complex Inhibitor Elsevier Combination Therapy Elsevier DAA Elsevier Antiviral
topic_browse	ddc 610 ddc 570 fid BIODIV bkl 35.70 bkl 42.12 bkl 42.15 Elsevier NS5A Replication Complex Inhibitor Elsevier Combination Therapy Elsevier DAA Elsevier Antiviral
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	zu
author2_variant	e l el c h ch s d s sd sds a r ar h a t ha hat g t gt a t at m r b mr mrb s z sz s i s si sis n w nw w g wg s s l ss ssl d l dl s p sp h h hh j g jg s k f sk skf l v d lv lvd p h ph f m fm d h dh d c dc e c ec s n sn e a h ea eah
hierarchy_parent_title	Ubiquitin protease Ubp8 is necessary for
hierarchy_parent_id	ELV000307017
dewey-tens	610 - Medicine & health 570 - Life sciences; biology
hierarchy_top_title	Ubiquitin protease Ubp8 is necessary for
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)ELV000307017
title	Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection
ctrlnum	(DE-627)ELV013412817 (ELSEVIER)S0016-5085(14)01206-2
title_full	Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection
author_sort	Dore, Gregory J.
journal	Ubiquitin protease Ubp8 is necessary for
journalStr	Ubiquitin protease Ubp8 is necessary for
lang_code	eng
isOA_bool	false
dewey-hundreds	600 - Technology 500 - Science
recordtype	marc
publishDateSort	2015
contenttype_str_mv	zzz
container_start_page	355
author_browse	Dore, Gregory J.
container_volume	148
physical	3307
class	610 610 DE-600 570 VZ BIODIV DE-30 fid 35.70 bkl 42.12 bkl 42.15 bkl
format_se	Elektronische Aufsätze
author-letter	Dore, Gregory J.
doi_str_mv	10.1053/j.gastro.2014.10.007
dewey-full	610 570
title_sort	daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for hcv genotype 2 or 3 infection
title_auth	Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection
abstract	Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%–80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy.
abstractGer	Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%–80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy.
abstract_unstemmed	Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%–80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy.
collection_details	GBV_USEFLAG_U GBV_ELV SYSFLAG_U FID-BIODIV SSG-OLC-PHA
container_issue	2
title_short	Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection
url	https://doi.org/10.1053/j.gastro.2014.10.007
remote_bool	true
author2	Lawitz, Eric Hézode, Christophe Shafran, Stephen D. Ramji, Alnoor Tatum, Harvey A. Taliani, Gloria Tran, Albert Brunetto, Maurizia R. Zaltron, Serena Strasser, Simone I. Weis, Nina Ghesquiere, Wayne Lee, Samuel S. Larrey, Dominique Pol, Stanislas Harley, Hugh George, Jacob Fung, Scott K. de Lédinghen, Victor Hagens, Peggy McPhee, Fiona Hernandez, Dennis Cohen, David Cooney, Elizabeth Noviello, Stephanie Hughes, Eric A.
author2Str	Lawitz, Eric Hézode, Christophe Shafran, Stephen D. Ramji, Alnoor Tatum, Harvey A. Taliani, Gloria Tran, Albert Brunetto, Maurizia R. Zaltron, Serena Strasser, Simone I. Weis, Nina Ghesquiere, Wayne Lee, Samuel S. Larrey, Dominique Pol, Stanislas Harley, Hugh George, Jacob Fung, Scott K. de Lédinghen, Victor Hagens, Peggy McPhee, Fiona Hernandez, Dennis Cohen, David Cooney, Elizabeth Noviello, Stephanie Hughes, Eric A.
ppnlink	ELV000307017
mediatype_str_mv	z
isOA_txt	false
hochschulschrift_bool	false
author2_role	oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth oth
doi_str	10.1053/j.gastro.2014.10.007
up_date	2024-07-06T18:50:44.585Z
_version_	1803856741228609536
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV013412817</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623105037.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180602s2015 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1053/j.gastro.2014.10.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015021000015.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV013412817</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0016-5085(14)01206-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">BIODIV</subfield><subfield code="q">DE-30</subfield><subfield code="2">fid</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">35.70</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.12</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">42.15</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Dore, Gregory J.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">3307</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Twenty-four weeks of treatment with peginterferon and ribavirin for chronic hepatitis C virus (HCV) genotype 2 or 3 infection produces a sustained virologic response (SVR) in 70%–80% of patients. We performed a randomized, double-blind, phase 2b study to assess whether adding daclatasvir, a nonstructural protein 5A (NS5A) inhibitor that is active against these genotypes, improves efficacy and shortens therapy.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NS5A Replication Complex Inhibitor</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Combination Therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">DAA</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antiviral</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lawitz, Eric</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hézode, Christophe</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shafran, Stephen D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ramji, Alnoor</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tatum, Harvey A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Taliani, Gloria</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tran, Albert</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brunetto, Maurizia R.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Zaltron, Serena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Strasser, Simone I.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Weis, Nina</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ghesquiere, Wayne</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lee, Samuel S.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Larrey, Dominique</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pol, Stanislas</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Harley, Hugh</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">George, Jacob</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fung, Scott K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Lédinghen, Victor</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hagens, Peggy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">McPhee, Fiona</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hernandez, Dennis</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cohen, David</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cooney, Elizabeth</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Noviello, Stephanie</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hughes, Eric A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">HighWire Press</subfield><subfield code="a">Leo, Manuela ELSEVIER</subfield><subfield code="t">Ubiquitin protease Ubp8 is necessary for</subfield><subfield code="d">2018</subfield><subfield code="d">official publication of the American Gastroenterological Association</subfield><subfield code="g">Stanford, Calif</subfield><subfield code="w">(DE-627)ELV000307017</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:148</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:355-3661</subfield><subfield code="g">extent:3307</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1053/j.gastro.2014.10.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">FID-BIODIV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">35.70</subfield><subfield code="j">Biochemie: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.12</subfield><subfield code="j">Biophysik</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">42.15</subfield><subfield code="j">Zellbiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">148</subfield><subfield code="j">2015</subfield><subfield code="e">2</subfield><subfield code="h">355-3661</subfield><subfield code="g">3307</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
score	7.4018183

Nicht das Richtige dabei?

Schreiben Sie uns!

Daclatasvir Plus Peginterferon and Ribavirin Is Noninferior to Peginterferon and Ribavirin Alone, and Reduces the Duration of Treatment for HCV Genotype 2 or 3 Infection

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?